1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68149EC900BBCA92E85257906006F36BD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/activities-budget-for-optimizing-pharmaceutical-education-groups?opendocument
18
19opendocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Education

Professional Medical Education Excellence: Activities and Budget to Optimize Pharmaceutical Education Groups

ID: 5149


Features:

Metrics, Graphics


Pages/Slides: 54


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Professional Medical Education Excellence: Activities and Budget to Optimize Pharmaceutical Education Groups"

STUDY OVERVIEW

The pharmaceutical sector's expanding global marketplace highlights the need for medical education groups that can adapt to new regions of the world as well as technologies for delivering programs. The challenge for many education groups is to manage an expansion of education programs and utilization of new technologies for training in the current fiscal environment.

Best Practices, LLC conducted this study to inform education leaders in the pharmaceutical sector on current approaches to budgets, technology, and staff roles. The study also includes benchmarks on budget allocations globally and technologies most effective for program delivery.

Medical education leaders can use this research to see how and where other organizations are allocating their funds for training. In addition, the study explores the roles of staff for critical activities, uses of technology for training and future trends in medical education.

This study presents data in two segments: Medical Device and Pharmaceutical

KEY TOPICS

  • Executive Summary
  • Participant Overview Information
  • Roles for Key Activities & Program Deployment
  • Budget Benchmarks & Allocation Trends
  • Trends & Directions

SAMPLE KEY METRICS
  • Roles played by Medical Education function regarding thought leaders
  • Roles played by Medical Education function regarding professional societies
  • Roles played by Medical Education function regarding education programs
  • Roles played by Medical Education function regarding compliance
  • Estimate of the total medical education programs deployed across various global areas
  • Various deployment approaches used for delivering medical education programs
  • Estimate of number of medical education programs carried out at different regions
  • Estimate in U.S. dollars medical education budget as a percentage of the revenues/sales support
  • Investment allocation by medical education groups with respect to annual budget
  • Budget allocation by region
  • Budget allocation by type of program
  • Future Allocations for Different Technologies
  • Future trends for technology based education programs over next 24 months
  • Future trends for technology spending over next 24 months

SAMPLE KEY FINDING
  • Medical Education budgets appear likely to grow in the device sector and potentially shrink in the pharma sector. On the device side, participants’ mean and median Medical Education budget represented 1.4 percent of the revenues supported by Medical Education. Pharma participants, meanwhile, produced a mean Medical Education budget of .72 percent of the revenues supported. Device MedEd budgets are generally larger than pharma because of the technology, faculty and FTEs involved in device education – industry simulation centers continue to open, adding FTEs and overhead costs in return for cutting-edge training for a wide range of physician types. In pharma, budgets are under pressure as companies cut back as part of the fallout over past criticism of commercial ties to education. Some have moved to only support independent education.

METHODOLOGY

The research employed a data gathering approach that reaps quantitative & qualitative data from representatives at 35 medical device and pharmaceutical companies. Fourteen participants from 10 medical device companies participated; 25 biopharma organizations participated.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Consulting; Research; Medical Device; Chemical; Consumer Products; Orthopaedics


Companies Profiled:
Abbott; Dendreon Corporation; Gilead Sciences; Epigenomics AG; Boehringer Ingelheim; Manthan Services; GlaxoSmithKline; Alcon Laboratories; Ipsen; Boston Scientific; Johnson & Johnson; Amylin; Laboratories Esteve; Bristol-Myers Squibb; MedImmune; Astellas; Medtronic; Celgene; Mitsubishi Tanabe Pharma; AstraZeneca; Novo Nordisk; Cephalon; Orthofix; Inc.; Pfizer; Baxter Healthcare; Regeneron; Cubist Pharmaceuticals; Roche; Bayer Healthcare; Sanofi-Aventis; EMD Serono; Shire; Biogen Idec; Smith & Nephew; Stryker; Takeda Pharmaceuticals; Zimmer

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.